Trial-Results center  
Clinical trial results database Feedback    Home


Related trials

APPRAISE-1 (10mg od), 2009 - apixaban vs placebo

SEPIA-ACS1 TIMI 42, 2009 - otamixaban vs unfractioned heparin

PLATO, 2009 - ticagrelor + aspirin vs clopidogrel + aspirin

ATLAS ACS-TIMI 46, 2009 - rivaroxaban vs placebo

APPRAISE-1 (2.5 mg bid), 2009 - apixaban vs placebo

DISPERSE-2 (90mg), 2007 - ticagrelor + aspirin vs clopidogrel + aspirin

INTERACT, 2006 - enoxaparin vs UFH (on top of aspirin)

OASIS 5, 2006 - fondaparinux vs enoxaparin

PROTECT-TIMI 30, 2006 - Bivalirudin vs eptifibatide + heparin

SYNERGY, 2005 - enoxaparin vs UFH (on top of aspirin)

EVET, 2005 - enoxaparin vs tinzaparin

LoWASA, 2004 - warfarin vs control (on top of aspirin)

PENTUA, 2004 - fondaparinux vs enoxaparin

Zibaeenezhad, 2004 - warfarin vs control (on top of aspirin)

APRICOT-2, 2002 - warfarin vs control (on top of aspirin)

ASPECT-2 (coumadin+asp vs asp), 2002 - coumadin vs control (on top of aspirin)

WARIS, 2002 - warfarin vs control (on top of aspirin)

ASPECT-2 (coumadin vs aspirin), 2002 - coumadin vs aspirin

CHAMP, 2002 - warfarin vs control (on top of aspirin)

OASIS-2 Warfarin Substudy, 2001 - warfarin vs control (on top of aspirin)

CURE, 2001 - clopidogrel + aspirin vs aspirin

Huyhn, 2001 - warfarin vs placebo (on top of aspirin)

TIM, 2000 - triflusal vs aspirine

HIT-4, 1999 - Hirudin vs heparin

Klootwijk, 1999 - Efegatran vs heparin



See also:

  • All acute coronary syndrome clinical trials
  • All clinical trials of antithrombotics
  • All clinical trials of triflusal
    		•  

    Plaza study, 1993

    Treatments

    Studied treatment triflusal 300 mg three times daily
    Control treatment placebo

    Patients

    Patients patients with unstable angina

    Method and design

    Randomized effectives 143 / 138 (studied vs. control)
    Design Parallel groups
    Blinding double blind
    Follow-up duration 6m
    Number of centre 10
    Geographic area Spain
    Hypothesis vascular death, MI


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    Non fatal MI

    6 / 143
         17 / 138
         0,34 [0,14;0,84]

    Vascular events

    8 / 143
         17 / 138
         0,45 [0,20;1,02]

    Major bleeding

    0 / 143
         0 / 138
         classic 0,97 [0,00;245,47]

    Vascular death

    2 / 143
         0 / 138
         classic 8,69 [0,14;537,57]

    Non vascular death

    0 / 143
         0 / 138
         classic 0,97 [0,00;245,47]

    Revascularization

    24 / 143
         28 / 138
         0,83 [0,51;1,35]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    Non fatal MI 6 / 143 (4,2%) 17 / 138 (12,3%) 0,34 [0,14;0,84]    
    Vascular death 2 / 143 (1,4%) 0 / 138 (0,4%) 3,86 [0,18;84,85]    
    Non vascular death 0 / 143 (0,3%) 0 / 138 (0,4%) 0,97 [0,02;48,30]    
    Revascularization 24 / 143 (16,8%) 28 / 138 (20,3%) 0,83 [0,51;1,35]    
    Vascular events 8 / 143 (5,6%) 17 / 138 (12,3%) 0,45 [0,20;1,02]    
    Major bleeding 0 / 143 (0,3%) 0 / 138 (0,4%) 0,97 [0,02;48,30]    
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 0:

    • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    Non fatal MI 4,20% 12,32% -81,2‰
    Revascularization 16,78% 20,29% -35,1‰
    Vascular events 5,59% 12,32% -67,2‰


    Reference(s)

    Trials register # NA
    • Plaza L, Lopez-Bescos L, Martin-Jadraque L, Alegria E, Cruz-Fernandez JM, Velasco J, Ruiperez JA, Malpartida F, Artal A, Cabades A. Protective effect of triflusal against acute myocardial infarction in patients with unstable angina: results of a Spanish multicenter trial. Grupo de Estudio del Triflusal en la Angina Inestable.. Cardiology 1993;82:388-98
      Pubmed | Hubmed | Fulltext

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend